Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Multiple Myeloma 60 Recurrence 11 Neoplasms, Plasma Cell 3 Smoldering Multiple Myeloma 2 Hematologic Neoplasms 2 Primary Myelofibrosis 1 Polycythemia Vera 1 Neoplasms 1 Lymphoma 1 Leukemia, Plasma Cell 1 Leukemia, Myeloid, Acute 1 Immunoglobulin Light-chain Amyloidosis 1

Interventions

Cyclophosphamide 447 Rituximab 406 Etoposide 225 Vincristine 217 Doxorubicin 204 Filgrastim 201 Prednisone 178 Cytarabine 160 Radiotherapy 152 fludarabine phosphate 148 Methotrexate 137 Peripheral Blood Stem Cell Transplantation 130 Melphalan 128 fludarabine 116 Busulfan 101 Dexamethasone 93 Tacrolimus 76 Carmustine 74 Granulocyte Colony-Stimulating Factor 73 Mycophenolic Acid 72 Gemcitabine 66 Bortezomib 65 Antilymphocyte Serum 65 Whole-Body Irradiation 63 Bendamustine Hydrochloride 63 Lenalidomide 62 Cyclosporine 62 Ifosfamide 58 sargramostim 51 Methylprednisolone 49

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma × elotuzumab × Clear all

NCT01239797 2022-06-01

ELOQUENT - 2

Bristol-Myers Squibb

Phase 3 Completed

646 enrolled 16 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡